Drug intelligence / Profile preview

PJ004

Development stage
Phase 2
Lead developer
Chongqing Peg-Bio Biopharm
Modality
Recombinant Proteins and Enzymes, Peptides
Administration
Subcutaneous
01

Overview

PJ004 (also known as PN20) is a pegylated thrombopoietic peptide being developed by Chongqing Peg-Bio Biopharm for the treatment of immune thrombocytopenia (ITP). It functions as a thrombopoietin receptor agonist (TPO-RA), designed to stimulate platelet production by binding to the thrombopoietin receptor (MPL) on megakaryocyte progenitor cells. As a pegylated biologic, it is intended for long-acting therapeutic effect and is administered via subcutaneous injection. In June 2024, the drug received approval from China's National Medical Products Administration (NMPA) to initiate clinical trials for primary ITP. It is currently undergoing Phase 1b clinical evaluation to assess its safety, tolerability, pharmacokinetics, and preliminary efficacy in adult patients.

Brand names
Plinest
Other names
pegylated thrombopoietic peptide
02

Targets

TPOR (Thrombopoietin receptor)

Beyond the preview

Go deeper on PJ004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PJ004.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call